Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Intra-Cellular Ther (ITCI)
Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,313,850
  • Shares Outstanding, K 95,926
  • Annual Sales, $ 250,310 K
  • Annual Income, $ -256,260 K
  • 60-Month Beta 1.13
  • Price/Sales 25.02
  • Price/Cash Flow N/A
  • Price/Book 9.95
Trade ITCI with:

Options Overview Details

View History
  • Implied Volatility 45.01% ( -2.96%)
  • Historical Volatility 26.54%
  • IV Percentile 5%
  • IV Rank 7.23%
  • IV High 74.62% on 02/21/23
  • IV Low 42.70% on 05/10/23
  • Put/Call Vol Ratio 1.55
  • Today's Volume 51
  • Volume Avg (30-Day) 306
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 5,566
  • Open Int (30-Day) 6,561

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.64
  • Number of Estimates 6
  • High Estimate -0.58
  • Low Estimate -0.69
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +30.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.33 +12.84%
on 06/01/23
66.56 -1.11%
on 05/10/23
+1.88 (+2.94%)
since 05/09/23
3-Month
42.01 +56.68%
on 03/10/23
66.56 -1.11%
on 05/10/23
+21.58 (+48.78%)
since 03/09/23
52-Week
42.01 +56.68%
on 03/10/23
66.56 -1.11%
on 05/10/23
+10.34 (+18.64%)
since 06/09/22

Most Recent Stories

More News
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

ITCI : 65.82 (+0.83%)
RCUS : 21.10 (-2.50%)
ALLO : 5.64 (-2.76%)
OCUP : 3.76 (-5.05%)
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 65.82 (+0.83%)
BCDA : 2.12 (unch)
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 65.82 (+0.83%)
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

ITCI : 65.82 (+0.83%)
ACAD : 24.72 (-1.47%)
AXSM : 73.74 (-1.99%)
APTX : 0.0721 (+1.55%)
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ITCI : 65.82 (+0.83%)
EXAS : 87.81 (-3.13%)
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

ITCI : 65.82 (+0.83%)
AXSM : 73.74 (-1.99%)
APTX : 0.0721 (+1.55%)
ANVS : 13.60 (-1.66%)
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.

REGN : 746.52 (-0.48%)
INCY : 61.04 (-0.76%)
ITCI : 65.82 (+0.83%)
VKTX : 24.27 (-2.10%)
BMEA : 40.90 (-2.15%)
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

ITCI : 65.82 (+0.83%)
RVNC : 29.87 (-4.05%)
Why Intra-Cellular Therapies Climbed Tuesday

The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.

ITCI : 65.82 (+0.83%)
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 15, 2023 – USA News Group  –  According to a 2022 study of more than 6 million patients 65 and older, the risk factor...

MRVL.VN : 0.090 (unch)
BIIB : 308.88 (+1.31%)
PRTA : 69.50 (-0.64%)
ITCI : 65.82 (+0.83%)
RHHBY : 39.1500 (-0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 67.50
2nd Resistance Point 66.71
1st Resistance Point 66.27
Last Price 65.82
1st Support Level 65.04
2nd Support Level 64.25
3rd Support Level 63.81

See More

52-Week High 66.56
Last Price 65.82
Fibonacci 61.8% 57.18
Fibonacci 50% 54.28
Fibonacci 38.2% 51.39
52-Week Low 42.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar